BIOS Insider Trading Activity and SEC Form 4 Filings
BIOS insider trading summary
No open-market insider purchases or sales of BioScrip, Inc. (BIOS) have been reported on SEC Form 4 in the past 12 months.
Latest BIOS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 9, 2017 | Stephen Deitsch | Chief Financial Officer | Buy | $20K (10,000 @ $2.03) |
| Nov 9, 2017 | Daniel E Greenleaf | Chief Executive Officer | Buy | $30K (15,000 @ $2.03) |
| Sep 15, 2017 | Michael G Bronfein | Director | Sell | $73K (27,000 @ $2.69) |
| Sep 7, 2017 | Adam Gray | Director | Sell | $3.7M (1,275,637 @ $2.88) |
| Sep 7, 2017 | Coliseum Capital Partners, L.P. | Director | Sell | $3.7M (1,275,637 @ $2.88) |
| Sep 7, 2017 | Christopher S Shackelton | Director | Sell | $3.7M (1,275,637 @ $2.88) |
| Sep 7, 2017 | Coliseum Capital Partners II, L.P. | Director | Sell | $3.7M (1,275,637 @ $2.88) |
| Sep 7, 2017 | Coliseum Capital Management, LLC | Director | Sell | $3.7M (1,275,637 @ $2.88) |
| Sep 7, 2017 | Coliseum Capital, LLC | Director | Sell | $3.7M (1,275,637 @ $2.88) |
| Sep 6, 2017 | Coliseum Capital Partners II, L.P. | Director | Sell | $4.0M (1,349,475 @ $2.96) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.